This inventor holds 1 USPTO granted patent and 3 published patent applications and 3 EPO patents. Top assignee: Shenzhen Kangsu Pharmaceutical Technology Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Shancun Ling - Innovator in TRK Kinase Inhibitor Compounds
Introduction
Shancun Ling is an inventor based in Zhenghou, China. He is known for his work in the field of medicinal chemistry, particularly focusing on TRK kinase inhibitor compounds. Although he currently holds no granted patents, his contributions to the field are noteworthy.
Latest Patent Applications
Shancun Ling's latest patent application is titled "TRK KINASE INHIBITOR COMPOUND AND USE THEREOF." This application relates to TRK kinase inhibitor compounds and their use in medicine. Specifically, it discloses a compound represented by formula (I), along with isotopically labeled compounds, optical isomers, geometric isomers, tautomers, or isomer mixtures. Additionally, it covers pharmaceutically acceptable salts, prodrugs, and metabolites of the compound.
Conclusion
Shancun Ling's innovative work in TRK kinase inhibitors highlights his potential impact on medicinal chemistry, despite not having any granted patents at this time.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile